These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 2012752

  • 1. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
    Estey EH, Kurzrock R, Talpaz M, McCredie KB, O'Brien S, Kantarjian HM, Keating MJ, Deisseroth AB, Gutterman JU.
    Br J Haematol; 1991 Mar; 77(3):291-5. PubMed ID: 2012752
    [Abstract] [Full Text] [Related]

  • 2. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.
    Kurzrock R, Talpaz M, Gutterman JU.
    Am J Med; 1992 Jul; 93(1):41-8. PubMed ID: 1626572
    [Abstract] [Full Text] [Related]

  • 3. Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients.
    Kurzrock R, Talpaz M, Gomez JA, Estey EH, O'Brien S, Hirsch-Ginsberg C, Koller C, Freireich EJ, Gutterman JU.
    Br J Haematol; 1991 Jul; 78(3):352-8. PubMed ID: 1873220
    [Abstract] [Full Text] [Related]

  • 4. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.
    Negrin RS, Haeuber DH, Nagler A, Olds LC, Donlon T, Souza LM, Greenberg PL.
    Ann Intern Med; 1989 Jun 15; 110(12):976-84. PubMed ID: 2471429
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group.
    Willemze R, van der Lely N, Zwierzina H, Suciu S, Solbu G, Gerhartz H, Labar B, Visani G, Peetermans ME, Jacobs A.
    Ann Hematol; 1992 Apr 15; 64(4):173-80. PubMed ID: 1581405
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors].
    Berthaud P, Eugène-Jolchine I, Spielmann M, Le Chevalier T, Tursz T.
    Bull Cancer; 1993 May 15; 80(5):418-30. PubMed ID: 8173195
    [Abstract] [Full Text] [Related]

  • 11. Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birthweight neonates: significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils.
    Cairo MS, Christensen R, Sender LS, Ellis R, Rosenthal J, van de Ven C, Worcester C, Agosti JM.
    Blood; 1995 Oct 01; 86(7):2509-15. PubMed ID: 7670096
    [Abstract] [Full Text] [Related]

  • 12. Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF.
    Zwierzina H, Herold M, Schöllenberger S, Geissler D, Schmalzl F.
    Br J Haematol; 1991 Nov 01; 79(3):438-43. PubMed ID: 1751371
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
    Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU.
    Exp Hematol; 1992 Jun 01; 20(5):558-64. PubMed ID: 1587302
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy.
    Neidhart JA, Mangalik A, Stidley CA, Tebich SL, Sarmiento LE, Pfile JE, Oette DH, Oldham FB.
    J Clin Oncol; 1992 Sep 01; 10(9):1460-9. PubMed ID: 1517789
    [Abstract] [Full Text] [Related]

  • 18. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
    Economopoulos T, Mellou S, Papageorgiou E, Pappa V, Kokkinou V, Stathopoulou E, Pappa M, Raptis S.
    Leukemia; 1999 Jul 01; 13(7):1009-12. PubMed ID: 10400415
    [Abstract] [Full Text] [Related]

  • 19. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
    Mangan K, Mullaney M, Klumpp T, Goldberg S, Macdonald J.
    Stem Cells; 1993 Sep 01; 11(5):445-54. PubMed ID: 8241955
    [Abstract] [Full Text] [Related]

  • 20. A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes.
    Bernell P, Stenke L, Wallvik J, Hippe E, Hast R.
    Leuk Res; 1996 Aug 01; 20(8):693-9. PubMed ID: 8913323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.